InMed Pharmaceuticals Inc. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from Q3 2021 to Q4 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
InMed Pharmaceuticals Inc. quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from Q3 2021 to Q4 2023.
- InMed Pharmaceuticals Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending December 31, 2023 was -$1.48M, a 29.5% increase year-over-year.
- InMed Pharmaceuticals Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending December 31, 2023 was -$6.35M, a 62.5% increase year-over-year.
- InMed Pharmaceuticals Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was -$7.93M, a 57.3% increase from 2022.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)